I have been holding off on my opinion from the proactive
I have been holding off on my opinion from the proactive update last week. I am somewhat depressed at this current turn of events. I don’t think it was optimistic to assume we would get BTD, the program was created for this very situation. I don’t blame Cytodyn for this, I blame the FDA for not lifting a finger to help. They know there is huge benefit to society to have leronlimab available to doctors, there is no doubt. At this point getting that to happen is pushed back no matter what indication you look at. I worry that the HIV bla is the shortest path right now and we might get more road blocks after the bla is filed. I hate that Nader said we are now sending the Nash data to thousands, that sounds like they are cold calling and desperate. I thought we were much further along with real partners.
As for Covid, there is no reason to stop gathering data from trials even if we are in the endemic. It might seem like we missed the boat but the wealth of education for what this drug can do and how it works is invaluable. Also, long Covid will be the headline after the spikes diminish. We are the only drug in this and we are hitting the ground running. The news that treated patients in our trials not only recovered but don’t have long haulers hopefully will be noticed.
I am most angry at Amarex, if they had not been so incompetent, we would be revenue generating and fda approved entering all these indications. There would be no Fife funding, there would be no slow enrollments and there would be no need for partners in Nash and cancer. The damage done by them is huge. I hope soon we will see the full force from Sidley to pull every cent we can from them in the most public way. All other small biotechs need this lack of service in the CRO industry. I do blame Cytodyn for sticking with them and telling us the whole time things are getting straitened out, but I know vendors at the time can lead you to believe sticking with them is the most reasonable path. If investors really know what was going on we possible would not have Cytodyn as an investment at all.
15
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Fresh Perspective on Portable Projection If anyone had told me a tech brand would buddy up with the world of fine art to launch a new gadget line, I'd have raised an eyebrow. But here we are, shrugging away the standard and looking at what's cooking over at Aurzen. The company's new initiative, 'Unfold the Art,' marries the magnetism of Jean-Michel Basquiat's artwork...
Continue Reading
Elevating Maternity Fashion with PinkBlush's Fall 2026 Line You know, it's not every day you see maternitywear aiming to push the envelope, but that's exactly what PinkBlush is doing this fall. They've unleashed their Fall 2026 collection, and let's just say, it's less about the frills and more about redefining what expecting mothers can expect from the fashion world. A...
Continue Reading
Lake Martin's New Residential Offering Step aside, beaches and mountains. Now it's all about lakeside living with some good old Alabama charm. Lennar, a heavyweight in the homebuilding scene, is opening the gates to The Oaks at Eclectic—a fresh batch of single-family homes sprouting near Lake Martin in Eclectic, Alabama. This spot is practically a haven for those who...
Continue Reading
In the ever-evolving landscape of pharmaceuticals, Lupin Limited's recent triumph snagging FDA approval for their Modafinil Tablets was a move you couldn't miss even if you'd tried. While the rooms of Mumbai and boardrooms around the globe might have been abuzz, investors should tune in to the humming potential of this development—especially if they're navigating the...
Continue Reading
In the world of AI-driven applications, data retention has become a hot potato, especially when we're talking about sensitive information like conversation records and audit logs. FastGPT, an open-source AI platform, has decided to tell it like it is by detailing exactly how these data pieces are retained and ultimately booted out. All this info was scattered to the winds...
Continue Reading
AI-Powered Revolution in Credit Disputes Alright, here we are staring down the latest twist in the credit game. CreditRefresh, an AI-driven platform out of Dover, Delaware, has managed to kickstart its journey by challenging over 1,000 credit report errors in just its first month on the market. That's quite a sprint straight from the gate, don't you think? But hey, this...
Continue Reading
Building Bridges Through Community Investment Well, ain't this something? Columbia, Tennessee, just got a splash of fresh air. We're talking about the new Southern Regional Technology Center nested in Columbia State Community College. Now, the name on everyone's lips? The TriStar Bank Community Room. But it ain't just about a name plastered up on a wall inside a shiny...
Continue Reading
Big Moves from Fujifilm's Camp Now we're talking, Fujifilm! Just when you think they might ease off the throttle, they crank up the heat with the XF 400mm f/4.5 R LM OIS WR lens. This isn’t just your run-of-the-mill update. It's a significant addition to their already beefed-up lineup for sports and wildlife. You know what that means: more reach, less baggage. Compact...
Continue Reading
A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...
Continue Reading
Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...
Continue Reading
Top 5 Most Recently Viewed Articles
Canadian Life Companies Split Corp. Dividend Announcement Canadian Life Companies Split Corp. is excited to announce the declaration of its monthly dividend distributions. For each Class A share, the corporation will distribute $0.10000, and for each Preferred share, a distribution of $0.05833 has been set. These distributions will be payable on November 10, 2025, to...
Continue Reading
Understanding the Quantum Corp. Lawsuit Recently, a class action lawsuit was initiated against Quantum Corporation, also known as Quantum Corp. This development stems from accusations regarding the company's financial reporting practices. The lawsuit suggests that the company may have incorrectly accounted for its revenue during the financial period that concluded in...
Continue Reading
Crucial Dates for Capricor Therapeutics Shareholders The Gross Law Firm has released an important notice for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm encourages anyone who purchased shares during the specified class period to connect with them regarding possible lead plaintiff appointments. Being appointed as the lead plaintiff isn't necessary...
Continue Reading
Understanding KBC Ancora's Voting Rights KBC Ancora periodically updates its shareholders on the total number of voting rights associated with its shares. As part of its compliance with the regulatory framework, specifically the Article 15 of the Act of 2 May 2007, KBC Ancora shares information about its capital, voting shares, and rights that might influence shareholder...
Continue Reading
Brenmiller Energy's Innovative Partnership for a Greener Future Brenmiller Energy Ltd. (Nasdaq: BNRG) has made a significant stride in the world of clean energy with the announcement of their bGen™ ZERO thermal energy storage system being selected for an ambitious project led by Resources of Biomass (REBI), a prominent Energy Service Company in Spain. This collaboration...
Continue Reading
